Fina Biosolutions LLC Profile last edited on: 10/13/21
CAGE: 4WZ88
UEI: DV4LJ9BSNXH7
Business Identifier: Affordable protein polysaccharide conjugates for vaccines 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 08
County: Montgomery
Congr. District: 08
County: Montgomery
Public Profile
Initially structured around enabling emerging market vaccine manufacturers to learn how to make affordable protein polysaccharide conjugates for vaccines, FinaBio is now a premier provider of conjugate vaccine laboratory and consulting services for the Biotech and Vaccine industry world-wide. Located in the heart of the Maryland biotechnology corridor, the firm offers a well-equipped laboratory for molecular biology and protein expression, conjugation, and conjugate vaccine characterization. Our scientists collaborate with universities such as Johns Hopkins and the University of Maryland, as well as the local biotechnology community to expand their resources.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
1-4Revenue Range
Less than .5MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 2024 | 1 | NIH | $297,809 | |
| Project Title: E. coli platform for expression of low-cost malaria fusion proteins | ||||
| 2020 | 1 | NIH | $289,089 | |
| Project Title: Genetically Detoxified Tetanus Toxin for Use in Vaccines | ||||
Key People / Management
Andrew Lees -- CEO and Chief Scientific Officer
Company News
There are no news available.
